All News
Diagnosis and Management of Kawasaki Disease
EurekAlert!
The journal Circulation has published a comprehensive overview called “Update on Diagnosis and Management of Kawasaki Disease,” summarizing data published since the 2017 American Heart Association Scientific Statement on Kawasaki Disease related to diagnostic criteria, risk scores and treatment options for children and adults with this condition.
Read Article
No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients
UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse cardiovascular events (MACE) in JAKi vs TNFi use in IBD.
Read Article
This interesting systematic review showed that the prevalence of ILD was 15% in patients with SLE. This higher than previously reported! #ACR24 @RheumNow https://t.co/O1aZUUL4Ho
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
Can we predict who will develop #RA-#ILD?
Wheeler et al showed a combination of genetic risk score, peripheral protein #biomarkers & clinical risk factors can help identify RA-ILD in RA patients.
Does this bring us closer to #PersonalisedMedicine?
Ab0799 #ACR24 @RheumNow https://t.co/JZkJNGmLM1
Mrinalini Dey DrMiniDey ( View Tweet)
Data from the French DESIR cohort reveals no significant link between high-dose NSAID use and incident hypertension in patients with axial spondyloarthritis. Two thirds were high dose NSAID users at baseline. Incident hypertension occurred in 11% individuals during follow-up.… https://t.co/EAICDwzxNT
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Serrano-Combarro et al. Abatacept in RA-ILD. 343 patients. In 23.3% ILD progressed on abatacept. Is that good or bad? We need comparative studies! @RheumNow #ACR24 Abstr#0475 https://t.co/nUEDdjGguA https://t.co/sXEF72MafK
Links:
Richard Conway RichardPAConway ( View Tweet)
Cardiology 🤝 Rheumatology
#Abstract0611 highlights Subclinical atherosclerosis (carotid plaque > 1.5 mm) associated with ↑ risk of CV events in SLE longitudinal cohort
@RheumNow #ACR24 https://t.co/jLLYNOfFZ2
Akhil Sood MD AkhilSoodMD ( View Tweet)
#0477 🌍 Global prevalence of RA-ILD
➡️21.38% (95% CI 0.15 - 0.29),33 studies, n=14,281
🔬 Higher RA-ILD risk in smokers, low-income regions, DMARD use.
⛔️Wide CI = heterogeneity main limitation
💡 Screening & lifestyle changes key for high-risk groups.
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
CKD keeps a persistent low grade inflammatory state! Implications: CKD ⬆️risk for CV dz through different mech @RheumNow #ACR24 https://t.co/KcCvyTVaav
TheDaoIndex KDAO2011 ( View Tweet)
Différent patterns of organ involvement in sarcoidosis @RheumNow #ACR24 #Sarcoidosis https://t.co/xigkS3vpUh
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Where do SGLT2i have proven benefits for CVD?
👉 Diabetes w/high CV risk
👉Heart failure (all EF)
👉CKD
Dr Weber @rheumnow #ACR24 https://t.co/vFYddrLP1Y
TheDaoIndex KDAO2011 ( View Tweet)
SELECT trial noted reduction in CV death, MI and stroke in obese pts without diabetes (other benefits: reduction in waist circumference, BP, lipids) @rheumnow # ACR24 https://t.co/GPK4Vg5bOt
Links:
TheDaoIndex KDAO2011 ( View Tweet)
#0322🔬 Myocarditis in Myositis(IIM)
📊 26% new IIM pt had myocarditis (ESC,Lake Louise)
💥 Anti-Ku most common MSA
💥Myocarditis a/w ⬆️heart failure, arrhythmia (43 v 6%;p=0.02)
🎯 Myocarditis🟰poor outcomes
🎯Cardiac MRI🟰earlier detection
#ACR24 @RheumNow @JuliePaikMD https://t.co/yz0f2ozFVL
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
#ACR24 Year in Review: 💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨) 💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?) 💡 High risk of CV events within 30 days of gout… https://t.co/XF63zr6lk4 https://t.co/oRNri66Il9
Links:
Adela Castro AdelaCastro222 ( View Tweet)
CV risk factors in rheumatic dz patients start in childhood. Patients with PMH of Kawasaki disease are at risk for rca/lmca aneurysms, thrombosis and stroke. Important to consider this with our history taking when pediatric patients transition to adult care! @RheumNow #ACR24 https://t.co/CIp8PjW4vD
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
CV risk after gout attack
1.75x increase risk of acute CV risk in first 30 days after gout flare (significant) possibly up to 120 days (didn’t reach significance)
@RheumNow
#ACR24 year in review Pillinger https://t.co/a2zS8mIw3L
Links:
Eric Dein ericdeinmd ( View Tweet)
Year in review: Can #gout flares increase CV risk?
Cipoletta et al - pts with gout may be at inc risk of CV events for at least 30-120 days after flares.
Emphasize CV risk mgt in all patients w/ gout.
@RheumNow #ACR24 https://t.co/p1aXVgqkuR
Links:
sheila RHEUMarampa ( View Tweet)
Diagnostic work up for sarcoidosis. Think of CVID as an important differential @RheumNow #ACR2024 #sarcoidosis https://t.co/DvJzkN3ZjY
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
VA #RA registry study of 263 RA-ILD pts (mean 69 yrs, 95% male, 73% W, 85% smokers), finds the MUC5B promoter variant in 33.5%. While the MUC5B variant is assoc w/ RA-ILD risk, it does not predict survival or mortality. Other genetic & nongenetic factor must be responsible… https://t.co/sr1AtAZRDT https://t.co/KKD7RLnIqR
Dr. John Cush RheumNow ( View Tweet)
Full read JAMA ILD Review article. ILD= 33% idiopathic (IPF) + 15% hypersensitivity pneumonitis + 25% from CTD.
30% of ILD has cough
Chest CT 91% sensitive, 71% specific
5% decr in FVC/12 mos assoc w/ 2-fold incr in mortality
Rx options nintedanib or pirfenidone, TCZ, MMF, RTX… https://t.co/9pET497zjC https://t.co/P8XVlVmmLd
Dr. John Cush RheumNow ( View Tweet)
